Search 

Exhibiting at booth 4

The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.

Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.

Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.

As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.

ApconiX are experts in ion channel biology, target safety assessments and in all aspects of nonclinical programme design and delivery.

ApconiX was formed by three AstraZeneca colleagues with the drive and ambition to create a world-renowned company founded on the skills and experience of a growing team with a wide range of expertise in nonclinical drug safety.

The model for the pharmaceutical industry has evolved in recent years with large pharma reducing internal capability and outsourcing key skills to trusted partners.  There are many more SMEs and academic groups who also need access to specialised services.

ApconiX addresses all needs by providing an exceptional group of scientists to these companies, in a cost-effective and flexible way.  In this way, companies work with people they trust, to make better decisions on drug safety.

Aptus Clinical is a specialist UK-based Clinical Contract Research Organisation (CRO) with particular expertise in oncology, rare diseases and advanced, cell and gene therapies. We have decades of experience in delivering complex and innovative trials, transforming potential into value.

We are proud to be part of iMATCH, a Manchester-based consortium which is one of only three centres in the UK to be awarded funding by Innovate UK to coordinate scale-up of advanced therapies for a range of debilitating conditions.

In partnering with life science companies, we can help transform promising molecules into valued medicines. We ensure early clinical development strategies are optimised and that Phase I/II studies are both innovatively designed and expertly delivered.

Arcinova is a UK based Contract Research and Development Organisation (CRDO) operating from a 15,000m2 site which has benefited from more than 36 years of investment as a key research and development centre. We provide the pharmaceutical industry with a comprehensive range of services, backed by extensive scientific expertise and strong practical capabilities.

We work to enhance the health and wellbeing of society by helping companies to develop life changing medicines and take them to market quickly, effectively and efficiently.

Our focus is on API process research, the development, validation and application of analytical, microbiological and materials science spectroscopic methodologies, scale-up and early phase clinical product manufacturing. We provide non-clinical and clinical 14C, API, drug product, bioanalysis, regulatory and consulting services.

Our mission at Arcinova is to delight our life sciences customers by satisfying their contract research, development and manufacturing needs with agility, innovation, seamless teamwork and best value delivery.

Clinical Network Services (CNS) is an integrated service group focused on product development, headquartered in Australia with offices in New Zealand, the UK and the USA, who create value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.

Curileum is a discovery stage company in London targeting defective mucosal stem cells that underpin serious gastrointestinal (GI) diseases and disorders with major GI complications.

• Licensing and product Development
• Spin out from UCL School of Pharmacy based on 20+ years research from laboratory of Prof. Abdul Basit
• Experts in oral drug delivery, range of licensable technologies for targeted delivery in GI tract
• Unique GI models that provide expert analysis of formulation behaviour under physiologically appropriate conditions

Karma Oncology is a specialist oncology clinical development company headquartered in Scotland with offices in Ireland, Netherlands and USA.  We offer a complete range of development services from clinical development planning, protocol design and authoring, strategic country/site selection, regulatory submissions, through to clinical trial execution and reporting.

With Karma, experience makes the difference - Our team has successfully completed programs in a broad range of solid tumour and hematologic indications utilizing an array of different therapeutic approaches including immunotherapy and autologous cell therapy and CAR-T cell therapy.

Karma is flexible - We can provide selected individual services, and extend to full-service global CRO capabilities as the program needs expand.  Our size allows us to be flexible, innovative and responsive to individual sponsor requirements and to adhere strictly to specified development timelines.

Karma is different - Our Project Managers have extensive oncology experience, our monitors are professional, mature 'career' CRAs - not trainees - and we have the lowest staff turnover in the industry (<5%).  Many of our staff come from a nursing or medical background, and for international studies we use CRAs native to their country.

LSX is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses. We achieve this through a programme of high-level conferences and networking events, via content that showcases and shares the expertise of investors, senior leaders and industry stakeholders, as well as through bespoke initiatives.

PHASTAR work with small and large pharmaceutical and biotechnology companies to provide statistical consulting and to summarise, analyse and report clinical trials.  Our top priority is the quality of our work, ensuring we give you the best statistical advice, and analyse your clinical data optimally, getting it right first time. There are lots of different ways to analyse a set of data. We can advise on how to get the most out of your data. Statistics is an art!

We can work with our own internal systems and processes or seamlessly incorporate with your teams. We can manage and deliver whole clinical trial programs, or give you advice on a trial you are planning.

Our vision is to become the supplier of choice for statistics to the pharma and biotech sector, by delivering quality advice and results, on time and on budget.